8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Feb 17, 2026·SEC
Material company update
Feb 6, 2026·SEC
Twist Bioscience Corporation(TWST)Earnings, Financials & Key Ratios
TWST•NASDAQ
Price updated Jun 19, 2026
AboutTwist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.Show more
- Revenue$377M+20.3%
- EBITDA-$111M+41.2%
- Net Income-$78M+62.8%
- EPS (Diluted)-1.30+63.9%
- Gross Margin50.72%+19.0%
- EBITDA Margin-29.58%+51.1%
- Operating Margin-36.18%+48.7%
- Net Margin-20.63%+69.1%
- ROE-16.43%+56.9%
TWST Key Insights
Twist Bioscience Corporation (TWST) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 96 (top 4%)
- ✓Strong 5Y sales CAGR of 33.1%
- ✓Trading near 52-week high
✗Weaknesses
- ✗Negative free cash flow
- ✗Expensive at 11.1x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TWST posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TWST Price & Volume
Twist Bioscience Corporation (TWST) stock price & volume — 10-year historical chart
Loading chart...
TWST Growth Metrics
Twist Bioscience Corporation (TWST) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years33.11%
3 Years22.76%
TTM17.77%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM57.48%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM59.2%
Return on Capital
10 Years-51.62%
5 Years-29.91%
3 Years-29.32%
Last Year-24.92%
TWST Recent Earnings
Twist Bioscience Corporation (TWST) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$0.62-26.5%
$0.49
Rev
$111M+2.9%
$108M
Q1 2026
Feb 2, 2026Metric
Actual
Est
EPS
$0.50-4.2%
$0.48
Rev
$104M+1.8%
$102M
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.45+10.0%
$0.50
Rev
$99M+1.7%
$97M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$0.47+13.0%
$0.54
Rev
$96M-1.4%
$97M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.62vs $0.49-26.5% | $111Mvs $108M+2.9% |
| Q1 2026 | Feb 2, 2026 | $0.50vs $0.48-4.2% | $104Mvs $102M+1.8% |
| Q4 2025 | Nov 14, 2025 | $0.45vs $0.50+10.0% | $99Mvs $97M+1.7% |
| Q3 2025 | Aug 4, 2025 | $0.47vs $0.54+13.0% | $96Mvs $97M-1.4% |
Based on last 12 quarters of dataView full earnings history →
TWST Peer Comparison
Twist Bioscience Corporation (TWST) competitors in Lab Consumables and Sample Preparation — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 | |
 PACB | 434.84M | 1.40 | -0.77 | 3.89% | -80.34% | -488.45% | 141.98 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 GH | 17.47B | 131.78 | -39.69 | 32.88% | -40.1% | |||
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 CDNA | 1.35B | 26.18 | -65.45 | 13.79% | -1.98% | -2.61% | 0.06 | |
 NTRA | 33.14B | 231.41 | -152.24 | 35.9% | -9.05% | -15.13% | 0.13 |
Compare TWST vs Peers
Twist Bioscience Corporation (TWST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TWST Income Statement
Twist Bioscience Corporation (TWST) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 10.77M | 25.43M | 54.38M | 90.1M | 132.33M | 203.56M | 245.11M | 312.97M | 376.57M | 409.48M |
Revenue Growth % | 374.53% | 136.16% | 113.89% | 65.67% | 46.87% | 53.83% | 20.41% | 27.69% | 20.32% | 17.77% |
Cost of Goods Sold | 24.02M | 32.19M | 47.43M | 61.41M | 80.62M | 119.33M | 155.38M | 179.63M | 185.57M | 196.25M |
COGS % of Revenue | 223.09% | 126.59% | 87.2% | 68.15% | 60.92% | 58.62% | 63.39% | 57.39% | 49.28% | - |
Gross Profit | -13.25M▲ 0% | -6.76M▲ 49.0% | 6.96M▲ 202.9% | 28.69M▲ 312.3% | 51.71M▲ 80.2% | 84.23M▲ 62.9% | 89.73M▲ 6.5% | 133.35M▲ 48.6% | 191M▲ 43.2% | 213.23M▲ 0% |
Gross Margin % | -123.09% | -26.59% | 12.8% | 31.85% | 39.08% | 41.38% | 36.61% | 42.61% | 50.72% | 52.07% |
Gross Profit Growth % | -85.3% | 48.98% | 202.91% | 312.33% | 80.22% | 62.89% | 6.52% | 48.61% | 43.23% | - |
Operating Expenses | 45.23M | 63.8M | 115.81M | 168.77M | 204.44M | 319.01M | 306.89M | 354.18M | 327.26M | 352.05M |
OpEx % of Revenue | 420.07% | 250.9% | 212.94% | 187.32% | 154.49% | 156.71% | 125.2% | 113.17% | 86.91% | - |
Selling, General & Admin | 26.06M | 43.45M | 80.13M | 103.27M | 135.9M | 212.95M | 189.74M | 218.4M | 246.98M | 272.95M |
SG&A % of Revenue | 242.04% | 170.88% | 147.33% | 114.61% | 102.7% | 104.61% | 77.41% | 69.78% | 65.59% | - |
Research & Development | 19.17M | 20.35M | 35.68M | 43.01M | 69.07M | 120.31M | 106.89M | 90.85M | 80.28M | 71.89M |
R&D % of Revenue | 178.03% | 80.02% | 65.61% | 47.73% | 52.2% | 59.1% | 43.61% | 29.03% | 21.32% | - |
Other Operating Expenses | -55K | -121K | -265K | 22.5M | -534K | -14.24M | 10.26M | 44.93M | 0 | 1000K |
Operating Income | -58.48M▲ 0% | -70.56M▼ 20.7% | -108.85M▼ 54.3% | -140.08M▼ 28.7% | -152.73M▼ 9.0% | -234.78M▼ 53.7% | -217.16M▲ 7.5% | -220.83M▼ 1.7% | -136.26M▲ 38.3% | -138.82M▲ 0% |
Operating Margin % | -543.16% | -277.5% | -200.15% | -155.47% | -115.41% | -115.33% | -88.6% | -70.56% | -36.18% | -33.9% |
Operating Income Growth % | -33.96% | -20.65% | -54.27% | -28.69% | -9.03% | -53.72% | 7.5% | -1.69% | 38.3% | - |
EBITDA | -53.46M | -64.83M | -102.54M | -133.4M | -142.98M | -218.26M | -187.85M | -189.4M | -111.41M | -114.63M |
EBITDA Margin % | -496.53% | -254.97% | -188.54% | -148.06% | -108.04% | -107.22% | -76.64% | -60.52% | -29.58% | -27.99% |
EBITDA Growth % | -35.59% | -21.27% | -58.16% | -30.1% | -7.18% | -52.66% | 13.93% | -0.83% | 41.18% | 33.91% |
D&A (Non-Cash Add-back) | 5.02M | 5.73M | 6.31M | 6.68M | 9.75M | 16.51M | 29.31M | 31.43M | 24.85M | 24.19M |
EBIT | -58.13M | -69.68M | -106.08M | -138.76M | -153.66M | -228.19M | -203.46M | -208.14M | -76.95M | -82.42M |
Net Interest Income | -493K | -314K | 1.74M | 712K | 68K | 2.98M | 14.36M | 15.31M | 11.36M | 9.21M |
Interest Income | 412K | 999K | 3.03M | 1.5M | 435K | 3.06M | 14.37M | 15.34M | 11.36M | 9.21M |
Interest Expense | 905K | 1.31M | 1.29M | 787K | 367K | 80K | 5K | 29K | 0 | 0 |
Other Income/Expense | -548K | -435K | 1.47M | 530K | -1.3M | 6.5M | 13.69M | 12.66M | 59.31M | 58.28M |
Pretax Income | -59.03M▲ 0% | -70.99M▼ 20.3% | -107.38M▼ 51.2% | -139.55M▼ 30.0% | -154.03M▼ 10.4% | -228.27M▼ 48.2% | -203.47M▲ 10.9% | -208.17M▼ 2.3% | -76.95M▲ 63.0% | -80.53M▲ 0% |
Pretax Margin % | -548.25% | -279.21% | -197.44% | -154.88% | -116.39% | -112.14% | -83.01% | -66.51% | -20.43% | -19.67% |
Income Tax | 280K | 242K | 292K | 382K | -1.93M | -10.41M | 1.15M | 560K | 719K | 743K |
Effective Tax Rate % | -0.47% | -0.34% | -0.27% | -0.27% | 1.25% | 4.56% | -0.57% | -0.27% | -0.93% | -0.92% |
Net Income | -59.31M▲ 0% | -71.24M▼ 20.1% | -107.67M▼ 51.1% | -139.93M▼ 30.0% | -152.1M▼ 8.7% | -217.86M▼ 43.2% | -204.62M▲ 6.1% | -208.73M▼ 2.0% | -77.67M▲ 62.8% | -81.28M▲ 0% |
Net Margin % | -550.85% | -280.16% | -197.98% | -155.31% | -114.94% | -107.02% | -83.48% | -66.69% | -20.63% | -19.85% |
Net Income Growth % | -34.53% | -20.11% | -51.14% | -29.96% | -8.7% | -43.24% | 6.08% | -2.01% | 62.79% | 57.48% |
Net Income (Continuing) | -59.31M | -71.24M | -107.67M | -139.93M | -152.1M | -217.86M | -204.62M | -208.73M | -77.67M | -81.28M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -3.16▲ 0% | -2.68▲ 15.2% | -3.92▼ 46.3% | -3.57▲ 8.9% | -3.15▲ 11.8% | -4.04▼ 28.3% | -3.60▲ 10.9% | -3.60▲ 0.0% | -1.30▲ 63.9% | -1.32▲ 0% |
EPS Growth % | -34.47% | 15.19% | -46.27% | 8.93% | 11.76% | -28.25% | 10.89% | 0% | 63.89% | 59.2% |
EPS (Basic) | -3.16 | -2.68 | -3.92 | -3.57 | -3.15 | -4.04 | -3.60 | -3.60 | -1.30 | - |
Diluted Shares Outstanding | 18.78M | 26.61M | 27.46M | 39.19M | 48.25M | 53.88M | 56.88M | 58.02M | 59.81M | 61.7M |
Basic Shares Outstanding | 18.78M | 26.61M | 27.46M | 39.19M | 48.25M | 53.88M | 56.88M | 58.02M | 59.81M | 61.7M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TWST Balance Sheet
Twist Bioscience Corporation (TWST) balance sheet — assets, liabilities & shareholders' equity
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 67.87M | 95.67M | 160.13M | 334.87M | 546.5M | 596.48M | 424.26M | 346.78M | 332.97M | 323.44M |
Cash & Short-Term Investments | 62.2M | 80.76M | 138.11M | 290M | 477.86M | 504.97M | 336.41M | 276.4M | 232.43M | 171.67M |
Cash Only | 31.23M | 80.76M | 46.73M | 93.67M | 465.83M | 378.69M | 286.47M | 226.32M | 183.05M | 122.67M |
Short-Term Investments | 30.98M | 0 | 91.37M | 196.34M | 12.03M | 126.28M | 49.94M | 50.08M | 49.38M | 49M |
Accounts Receivable | 2.35M | 5.42M | 12.1M | 25.43M | 28.55M | 40.29M | 44.06M | 34.9M | 57.02M | 64.15M |
Days Sales Outstanding | 79.53 | 77.79 | 81.23 | 103 | 78.74 | 72.25 | 65.62 | 40.7 | 55.27 | 49.34 |
Inventory | 1.83M | 6.03M | 7.33M | 12.29M | 31.8M | 39.31M | 32.06M | 24.08M | 28.31M | 33.52M |
Days Inventory Outstanding | 27.76 | 68.35 | 56.41 | 73.05 | 143.97 | 120.23 | 75.32 | 48.93 | 55.68 | 56.11 |
Other Current Assets | 0 | 3.47M | 0 | 951K | 0 | 0 | 11.72M | 11.4M | 0 | 54.1M |
Total Non-Current Assets | 17.79M | 20.12M | 26.86M | 64.01M | 155.6M | 364.9M | 352.15M | 267.55M | 308.89M | 352.77M |
Property, Plant & Equipment | 14.83M | 12.33M | 20.84M | 59.16M | 105.7M | 214.39M | 203.36M | 161.35M | 151.66M | 181.88M |
Fixed Asset Turnover | 0.73x | 2.06x | 2.61x | 1.52x | 1.25x | 0.95x | 1.21x | 1.94x | 2.48x | 2.49x |
Goodwill | 1.14M | 1.14M | 1.14M | 1.14M | 22.43M | 85.81M | 85.81M | 85.81M | 82.19M | 82.19M |
Intangible Assets | 920K | 712K | 508K | 307K | 18.26M | 59.74M | 54.48M | 14.48M | 13.43M | 13M |
Long-Term Investments | 202K | 579K | 579K | 0 | 0 | 0 | 0 | 0 | 54.34M | 235.27M |
Other Non-Current Assets | 896K | 5.94M | 4.38M | 3.4M | 9.2M | 4.96M | 8.49M | 5.91M | 7.28M | 7.62M |
Total Assets | 85.66M▲ 0% | 115.79M▲ 35.2% | 186.99M▲ 61.5% | 398.88M▲ 113.3% | 702.1M▲ 76.0% | 961.38M▲ 36.9% | 776.4M▼ 19.2% | 614.32M▼ 20.9% | 641.86M▲ 4.5% | 676.21M▲ 0% |
Asset Turnover | 0.13x | 0.22x | 0.29x | 0.23x | 0.19x | 0.21x | 0.32x | 0.51x | 0.59x | 0.63x |
Asset Growth % | 12.02% | 35.18% | 61.49% | 113.31% | 76.02% | 36.93% | -19.24% | -20.88% | 4.48% | 23.72% |
Total Current Liabilities | 9.48M | 18.54M | 30.35M | 36.03M | 63.05M | 90.66M | 73.32M | 71.01M | 91.41M | 119.98M |
Accounts Payable | 2.85M | 7.53M | 9.76M | 4.83M | 14.9M | 20.09M | 14.05M | 1.63M | 11.09M | 14.68M |
Days Payables Outstanding | 43.29 | 85.4 | 75.11 | 28.71 | 67.46 | 61.46 | 33.01 | 3.31 | 21.82 | 23.37 |
Short-Term Debt | 0 | 2.5M | 3.33M | 3.33M | 1.55M | 0 | 0 | 0 | 13.82M | 10.44M |
Deferred Revenue (Current) | 0 | 7.57M | 16.44M | 0 | 1.09M | 3.48M | 0 | 2.13M | 6.88M | 22.23M |
Other Current Liabilities | 3.16M | 3.1M | 817K | 2.61M | 28.42M | 39.62M | 18.56M | 34.61M | 23.77M | 94.85M |
Current Ratio | 7.16x | 5.16x | 5.28x | 9.29x | 8.67x | 6.58x | 5.79x | 4.88x | 3.64x | 2.70x |
Quick Ratio | 6.97x | 4.84x | 5.03x | 8.95x | 8.16x | 6.15x | 5.35x | 4.54x | 3.33x | 2.42x |
Cash Conversion Cycle | 64 | 60.75 | 62.53 | 147.33 | 155.26 | 131.02 | 107.93 | 86.32 | 89.13 | 82.08 |
Total Non-Current Liabilities | 209.54M | 298.68M | 4.56M | 26.59M | 58.22M | 81.33M | 79.65M | 70.63M | 77.5M | 101.14M |
Long-Term Debt | 9.15M | 7.22M | 4.4M | 1.4M | 0 | 0 | 0 | 0 | 61.75M | 85.4M |
Capital Lease Obligations | 0 | 0 | 0 | 24.84M | 53.16M | 81.27M | 79.17M | 70.22M | 61.75M | 210.21M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 200.38M | 291.46M | 158K | 351K | 5.07M | 60K | 475K | 407K | -46M | 15.75M |
Total Liabilities | 219.01M | 317.21M | 34.91M | 62.62M | 121.28M | 171.99M | 152.97M | 141.63M | 168.9M | 221.12M |
Total Debt | 9.15M | 9.72M | 7.73M | 35.98M | 62.92M | 94.91M | 94.07M | 85.03M | 137.32M | 95.84M |
Net Debt | -22.07M | -71.04M | -39M | -57.69M | -402.91M | -283.77M | -192.4M | -141.29M | -45.73M | -26.83M |
Debt / Equity | - | - | 0.05x | 0.11x | 0.11x | 0.12x | 0.15x | 0.18x | 0.29x | 0.21x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.84x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.23x |
Interest Coverage | -64.23x | -53.07x | -81.98x | -176.32x | -418.69x | -2852.43x | -40692.20x | -7177.14x | - | - |
Total Equity | -133.36M▲ 0% | -201.42M▼ 51.0% | 152.08M▲ 175.5% | 336.26M▲ 121.1% | 580.82M▲ 72.7% | 789.38M▲ 35.9% | 623.43M▼ 21.0% | 472.69M▼ 24.2% | 472.96M▲ 0.1% | 455.09M▲ 0% |
Equity Growth % | -74.07% | -51.04% | 175.5% | 121.11% | 72.73% | 35.91% | -21.02% | -24.18% | 0.06% | 0.86% |
Book Value per Share | -7.10 | -7.57 | 5.54 | 8.58 | 12.04 | 14.65 | 10.96 | 8.15 | 7.91 | 7.38 |
Total Shareholders' Equity | -133.36M | -201.42M | 152.08M | 336.26M | 580.82M | 789.38M | 623.43M | 472.69M | 472.96M | 455.09M |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1K |
Retained Earnings | -139.62M | -210.85M | -318.52M | -458.45M | -610.55M | -828.42M | -1.03B | -1.24B | -1.32B | -1.39B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 33K | 87K | 181K | 87K | 546K | -1.84M | -756K | -522K | -627K | -639K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TWST Cash Flow Statement
Twist Bioscience Corporation (TWST) cash flow — operating, investing & free cash flow history
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -51.3M | -66.16M | -87.94M | -142.25M | -112.24M | -124.39M | -142.47M | -64.09M | -47.63M | -55.59M |
Operating CF Margin % | -476.47% | -260.21% | -161.69% | -157.89% | -84.82% | -61.1% | -58.13% | -20.48% | -12.65% | - |
Operating CF Growth % | -32.93% | -28.97% | -32.91% | -61.77% | 21.1% | -10.82% | -14.54% | 55.01% | 25.69% | 49.92% |
Net Income | -59.31M | -71.24M | -107.67M | -139.93M | -152.1M | -217.86M | -204.62M | -208.73M | -77.67M | -81.28M |
Depreciation & Amortization | 5.02M | 5.73M | 6.11M | 6.68M | 9.75M | 16.51M | 29.31M | 31.43M | 24.85M | 24.68M |
Stock-Based Compensation | 1.89M | 2.96M | 11.17M | 17.1M | 37M | 79.66M | 30.28M | 50.92M | 64.46M | 64.35M |
Deferred Taxes | 768K | 42K | -1.06M | -214K | 0 | 0 | -410K | 0 | 0 | 0 |
Other Non-Cash Items | 458K | 562K | 515K | -707K | 2.49M | 2.66M | 3.98M | 46.86M | -46.66M | -48.31M |
Working Capital Changes | -129K | -4.22M | 3M | -25.18M | -9.38M | -5.36M | -1.01M | 15.41M | -12.61M | -15.03M |
Change in Receivables | -1.62M | -3.07M | -6.68M | -14.27M | -2.2M | -9.62M | -4.32M | 8.44M | -22.38M | -14.54M |
Change in Inventory | -599K | -4.2M | -1.3M | -4.96M | -19.49M | -7.54M | 7.24M | 7.99M | -4.23M | -12.65M |
Change in Payables | 560K | 3.76M | 3.28M | -5.51M | 8.54M | 7.38M | -2.51M | -11.8M | 9.33M | 4.45M |
Cash from Investing | -9.87M | 26.87M | -104.81M | -114.65M | 156.16M | -232.93M | 50.61M | -3.07M | -24.76M | -44.44M |
Capital Expenditures | -6.59M | -3.69M | -14.76M | -9.87M | -27.06M | -101.86M | -27.78M | -5.08M | -28M | -39.45M |
CapEx % of Revenue | 61.24% | 14.5% | 27.13% | 10.95% | 20.45% | 50.04% | 11.33% | 1.62% | 7.44% | 9.63% |
Acquisitions | 266K | 17K | 21K | 104.78M | -483K | -8.16M | 5.86M | 0 | 2.5M | 2.5M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 120K | -434K | -90.05M | -104.78M | 0 | -5.75M | -5.86M | 0 | 0 | -5.1M |
Cash from Financing | 63.8M | 88.82M | 158.58M | 303.73M | 329.18M | 270.53M | 911K | 6.89M | 28.54M | 11.84M |
Debt Issued (Net) | -2M | 0 | -2.5M | -3.33M | -3.33M | -1.56M | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 65.6M | 90.85M | 156.21M | 293.14M | 313.01M | 262.07M | -4.41M | -3.98M | 13.54M | 6.26M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -2.42M | -10.85M | -7.75M | -4.41M | -3.98M | -16K | -15K |
Other Financing | 205K | -2.03M | 4.87M | 13.92M | 19.5M | 10.02M | 5.32M | 10.87M | 15M | 5.58M |
Net Change in Cash | 2.63M▲ 0% | 49.53M▲ 1782.6% | -34.14M▼ 168.9% | 46.85M▲ 237.2% | 373.11M▲ 696.4% | -87.1M▼ 123.3% | -90.98M▼ 4.5% | -60.15M▲ 33.9% | -43.27M▲ 28.1% | -88.09M▲ 0% |
Free Cash Flow | -57.9M▲ 0% | -69.85M▼ 20.7% | -102.69M▼ 47.0% | -152.12M▼ 48.1% | -139.31M▲ 8.4% | -226.24M▼ 62.4% | -170.25M▲ 24.7% | -69.17M▲ 59.4% | -75.63M▼ 9.3% | -95.14M▲ 0% |
FCF Margin % | -537.71% | -274.72% | -188.83% | -168.84% | -105.27% | -111.14% | -69.46% | -22.1% | -20.08% | -23.23% |
FCF Growth % | -29.17% | -20.65% | -47.02% | -48.13% | 8.43% | -62.41% | 24.75% | 59.37% | -9.34% | -45.27% |
FCF per Share | -3.08 | -2.63 | -3.74 | -3.88 | -2.89 | -4.20 | -2.99 | -1.19 | -1.26 | -1.54 |
FCF Conversion (FCF/Net Income) | 0.86x | 0.93x | 0.82x | 1.02x | 0.74x | 0.57x | 0.70x | 0.31x | 0.61x | 1.17x |
Interest Paid | 702K | 751K | 779K | 438K | 167K | 9K | 0 | 0 | 0 | 0 |
Taxes Paid | 6K | 179K | 291K | 172K | 101K | 246K | 420K | 344K | 683K | -16K |
TWST Key Ratios
Twist Bioscience Corporation (TWST) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -70.8% | -57.31% | -33.17% | -31.8% | -28.97% | -38.08% | -16.43% | -17.46% |
Return on Invested Capital (ROIC) | - | - | -72.19% | -53.65% | -50.18% | -51.52% | -34.78% | -43.45% | -26.94% | -24.47% |
Gross Margin | -123.09% | -26.59% | 12.8% | 31.85% | 39.08% | 41.38% | 36.61% | 42.61% | 50.72% | 52.07% |
Net Margin | -550.85% | -280.16% | -197.98% | -155.31% | -114.94% | -107.02% | -83.48% | -66.69% | -20.63% | -19.85% |
Debt / Equity | - | - | 0.05x | 0.11x | 0.11x | 0.12x | 0.15x | 0.18x | 0.29x | 0.21x |
Interest Coverage | -64.23x | -53.07x | -81.98x | -176.32x | -418.69x | -2852.43x | -40692.20x | -7177.14x | - | - |
FCF Conversion | 0.86x | 0.93x | 0.82x | 1.02x | 0.74x | 0.57x | 0.70x | 0.31x | 0.61x | 1.17x |
Revenue Growth | 374.53% | 136.16% | 113.89% | 65.67% | 46.87% | 53.83% | 20.41% | 27.69% | 20.32% | 17.77% |
Related:TWST Dividend History·TWST Revenue History·TWST Price History·TWST P/E History·TWST Financial Ratios·TWST Institutional Holders
TWST SEC Filings & Documents
Twist Bioscience Corporation (TWST) SEC filings — annual & quarterly reports (10-K, 10-Q)
TWST Frequently Asked Questions
Twist Bioscience Corporation (TWST) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Twist Bioscience Corporation (TWST) reported $409.5M in revenue for fiscal year 2025. This represents a 17947% increase from $2.3M in 2016.
Twist Bioscience Corporation (TWST) grew revenue by 20.3% over the past year. This is strong growth.
Twist Bioscience Corporation (TWST) reported a net loss of $81.3M for fiscal year 2025.
Dividend & Returns
Twist Bioscience Corporation (TWST) has a return on equity (ROE) of -16.4%. Negative ROE indicates the company is unprofitable.
Twist Bioscience Corporation (TWST) had negative free cash flow of $95.1M in fiscal year 2025, likely due to heavy capital investments.